High-risk pregnancy in a patient with pulmonary arterial hypertension due to congenital heart disease (PAH-CHD) with temporary shunt inversion and deoxygenation

被引:6
|
作者
Hohmann, Christopher [1 ]
Dumitrescu, Daniel [1 ]
Gerhardt, Felix [1 ]
Kramer, Tilmann [1 ]
Rosenkranz, Stephan [1 ]
Huntgeburth, Michael [2 ]
机构
[1] Univ Hosp Cologne, Heart Ctr, Dept Internal Med 3, Pulm Hypertens Ctr, Cologne, Germany
[2] Univ Hosp Cologne, Heart Ctr, Dept Internal Med 3, Ctr Grown Ups Congenital Heart Dis GUCH, Cologne, Germany
关键词
atrial septal defect; congenital heart disease; pulmonary arterial hypertension; pregnancy; shunt inversion; MANAGEMENT; STATEMENT; SURVIVAL;
D O I
10.1177/2045894019835649
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial septal defect (ASD) is one of the most frequent congenital heart diseases (CHD). Up to 10% of adults with an ASD develop pulmonary arterial hypertension (PAH, PAH-CHD) in their lifetime. Despite improved therapy options, gravidity remains a substantial risk for both maternal and neonatal mortality in PAH-CHD patients. In our patient, gravidity remained uncomplicated until week 32, under specific monotherapy with tadalafil, before onset of dyspnea and markedly increase of systolic pulmonary arterial pressure (PAP) was observed in echocardiography. Urgent Caesarian delivery was performed without any complications and a healthy baby was born. However, immediately afterwards, the patient desaturated (SpO2 65%, PaO2 37 mmHg) due to a shunt inversion with now right-to-left shunt through the residual ASD. She was admitted to our intensive care unit and specific PH therapy was escalated to a triple combination of tadalafil, ambrisentan, and iloprost. Hereafter, in a slow process of approximately three weeks, the patient's condition improved to baseline. This rare case of a young woman with high-risk pregnancy in PAH-CHD highlights the hemodynamic changes and treatment options during pregnancy in these patients and emphasizes the urgency of a close monitoring at specialized GUCH/PAH centers with experience in managing PAH under these circumstances.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Pulmonary-arterial Hypertension (PAH) associated with congenital Heart Disease (CHD)
    Campean, I. -A.
    JOURNAL FUR KARDIOLOGIE, 2015, 22 (11-12): : 288 - 289
  • [2] Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)
    Luo, Jun
    Li, Yuanchang
    Chen, Jingyuan
    Qiu, Haihua
    Chen, Wenjie
    Luo, Xiaoqin
    Chen, Yusi
    Tan, Yingjie
    Li, Jiang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of View
    Chen, I-Chen
    Dai, Zen-Kong
    ACTA CARDIOLOGICA SINICA, 2015, 31 (06) : 507 - 515
  • [4] Selexipag for pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) after defect correction: insights from the randomized controlled GRIPHON study
    Beghetti, M.
    Channick, R.
    Chin, K.
    Di Scala, L.
    Gaine, S.
    Ghofrani, H. A.
    Hoeper, M.
    Lang, I.
    McLaughlin, V.
    Preiss, R.
    Rubin, L.
    Simonneau, G.
    Sitbon, O.
    Tapson, V.
    Galie, N.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1243 - 1243
  • [5] Treatment Patterns in Congenital Heart Disease Associated Pulmonary Arterial Hypertension: Results from a Real-World PAH-CHD Study in the United States
    Awerbach, J. D.
    Paoli, C.
    Scott, M.
    Doad, G.
    Harley, J.
    Graham, D.
    Small, M.
    Panjabi, S.
    Reardon, L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S83 - S83
  • [6] Current Era Survival Of Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD)
    Leci, E.
    Palazzini, M.
    Sciarra, F.
    Sgro, F.
    Conficoni, E.
    Beciani, E.
    Bachetti, C.
    Manes, A.
    Galie, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [7] Current era survival of patients with pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD)
    Palazzini, M.
    Leci, E.
    Sciarra, F.
    Conficoni, E.
    Manes, A.
    Beciani, E.
    Bachetti, C.
    Sgro, F.
    Branzi, A.
    Galie, N.
    EUROPEAN HEART JOURNAL, 2011, 32 : 174 - 174
  • [8] A Meta-analysis: Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication
    Krasuski, R. A.
    Tobore, T.
    Studer, S.
    Jansa, P.
    Sitbon, O.
    Hoeper, M. M.
    Channick, R. N.
    Gaine, S.
    Lang, I. M.
    Chin, K. M.
    Pulido, T.
    Mehta, S.
    Torbicki, A.
    Sastry, B.
    Tang, X.
    McLaughlin, V.
    Reardon, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [9] Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)
    Ramjug, Sheila
    Billings, Catherine
    Bowater, Sarah
    Charalampopoulos, Athanasios
    Clift, Paul
    Elliot, Charlie
    Hurdman, Judith
    Jenkins, Petra
    Kiely, David
    Lewis, Robert
    Oliver, James
    Sabroe, Ian
    Condliffe, Robin
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [10] Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
    Rosenkranz Stephan
    Hossein-Ardeschir Ghofrani
    Maurice Beghetti
    Dunbar Ivy
    Arno Fritsch
    Gerrit Weimann
    Soundos Saleh
    Christian Apitz
    Reiner Frey
    BMC Pharmacology and Toxicology, 16 (Suppl 1)